

FUNAMIZU et al
Appl. No. 09/485,845
February 12, 2004

COPY

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-66. Canceled.

67. (Currently Amended) A compound selected from:

N-(2-Aminoethyl)-3-phenyl-2(R)-[2-(1,1,4-trioxo-2,3-dihydro-

[1,5]benzothiazepin-5-yl)-acetyl amino]propionamide;

~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionamide;~~

~~3-(3-Acetyl amino-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-N-[1(R)-(2-amino-ethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]propionamide;~~

~~N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-1,1,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)propionamide;~~

~~N-[1(R)-(3-Amino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-1,1,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)propionamide;~~

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(4-Aminobutylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

N-(4-Aminobutyl)-3-(naphthalen-2-yl)-2(R)-[2-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-acetyl amino]propionamide;

FUNAMIZU et al
Appl. No. 09/485,845
February 12, 2004

COPY

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]oxazepin-10-yl)propionamide;

~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3-dihydro-1H-(11aS)pyrrolo[2.1c][1,1]benzodiazepin-10-yl)propionamide;~~

~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionamide;~~

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

~~N-[1(R)-(4-Aminobutylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(1-methyl-2,5-dioxo-2,3,4,5-tetrahydro-benzo[e][1,1]diazepin-1-yl)propionamide;~~

~~N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-oxo-2,3-dihydro-benzo[1,4]oxazin-1-yl)propionamide;~~

~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-oxo-2,3-dihydro-benzo[1,4]oxazin-1-yl)propionamide;~~

~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionamide;~~

N-(2-Amino-2-methylpropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-propionylamino]propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-methyl-4-oxo-2,3-dihydro[1,5]benzothiazepin-5-yl)propionamide;

BEST AVAILABLE COPY

FUNAMIZU et al
Appl. No. 09/485,845
February 12, 2004

COPY

~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)butyramide;~~

~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-1-(3-oxo-2,3-dihydro-benzof[1,4]thiazin-1-yl)butyramide;~~

~~N-[1(R)-(3-Methylamino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;~~

~~N-[1(R)-(3-Methylamino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;~~

~~N-(1(R)-[(3-Aminopropyl)-methylcarbamoyl]-2-(naphthalen-2-yl)ethyl)-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;~~

~~N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-propionylamino]propionamide;~~

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;~~

~~N-[1(R)-(2-Amino-ethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;~~

~~N-(1(R)-[Bis-(3-aminopropyl)carbamoyl]-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;~~

~~N-[1(R)-(3-Amino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(1,1,4-trioxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;~~

~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(11-oxo-11H-~~

BEST AVAILABLE COPY

FUNAMIZU et al
Appl. No. 09/485,845
February 12, 2004

COPY

dibenzo[b,f][1,4]oxazepin-10-yl)butyramide;

~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-phenothiazin-10-yl propionamide;~~

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,11-dihydro-6H-dibenzo[b,f]azocin-5-yl)propionamide;~~

~~N-(3-Amino-2-hydroxypropyl)-2(R)-[3-(6-methoxy-3-oxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)propionylamino]-3-(naphthalen-2-yl)propionamide;~~

~~N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)2(R)-[3-(2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionylamino]propionamide;~~

~~N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)2(R)-[3-(2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionylamino]propionamide;~~

~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)pentanamide;~~

~~N-[1(R)-(2-aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)pentanamide;~~

~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(1H-indol-3-yl)-ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;~~

~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(5,6,7,8-tetrahydro-naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;~~

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]oxazepin-10-yl)propionamide;~~

FUNAMIZU et al
Appl. No. 09/485,845
February 12, 2004

COPY

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(1,4-dioxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzoxazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamyl)-2-(naphthalen-2-yl)ethyl]-3-(2-methyl-4-oxo-2,3-dihydro[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(7⁸-fluoro-4-oxo-[1,5]benzothiazepin-5-yl)propionamide;

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3-dihydro-1H,11aS-pyrrole[2,1-e][1,4]diazepin-10-yl)propionamide;~~

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(phenothiazin-10-yl)propionamide;~~

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)butyramide;~~

N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalene-2-yl)ethyl]-3-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalene-2-yl)-2(R)-[3-(4-oxo-7-trifluoromethyl-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionylamino]propionamide;

FUNAMIZU et al
Appl. No. 09/485,845
February 12, 2004

COPY

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)butyramide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)propionylamino]propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-(3-Amino-2-hydroxypropyl)-2(R)-[3-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionylamino]-3-(naphthalen-2-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(8-fluoro-4-oxo-[1,5]-benzothiazepin-5-yl)butyramide;

~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-exo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;~~

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-exo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;~~

~~N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;~~

~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;~~

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;~~

FUNAMIZU et al
Appl. No. 09/485,845
February 12, 2004

COPY

~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(6-oxo-6H-dibenzo[b,f]azocin-5-yl)pentanamide;~~

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(6-oxo-6H-dibenzo[b,f]azocin-5-yl)pentanamide;~~

~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]thiazepin-10-yl)propionamide;~~

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]-thiazepin-10-yl)propionamide;~~

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(5,11-dioxo-5,11-dihydrodibenzo-[b,f][1,4]thiazepin-10-yl)pentanamide;~~

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(5,5,11-trioxo-5,11-dihydro-dibenzo[b,f][1,4]thiazepin-10-yl)pentanamide;~~

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2,2-dimethyl-4-oxo-3,4-dihydro-2H-benzo[1,5]thiazepin-5-yl)propionamide;~~

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(7-chloro-5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrole[1,2-a][1,4]diazepine-10-yl)propionamide;~~

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,12-dioxo-6,6a,7,8,9,10-hexahydro-12H-benzo[e]pyrido[1,2-a][1,4]diazepine-5-yl)propionamide;~~

BEST AVAILABLE COPY

FUNAMIZU et al
Appl. No. 09/485,845
February 12, 2004

COPY

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(9-fluore-2-oxo-3,1,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionamide;
N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-2H-benzo[1,5]-thiazepin-5-yl)propionamide;
N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-2H-benzo[1,5]thiazepin-5-yl)propionamide;
N-[1(R)-(3-amino-2(S)-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-3,4-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;
N-[1(R)-(3-Amino-3-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[a]pyrrole[1,2-a][1,4]diazepine-10-yl)propionamide;
N-[1(R)-(3-amino-2(R)-hydroxy-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-3,4-dihydro-[1,5]-benzothiazepin-5-yl) butanamide;
N-[1(R)-(3-Amino-3-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2,2-dimethyl-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[a]pyrrole[1,2-a][1,4]diazepine-10-yl)propionamide;
N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2,2-dimethyl-3-(1,1,4-trioxo-benzo-[1,5]thiazepin-5-yl)propionamide;
N-[1(R)-(2-Amino-ethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

BEST AVAILABLE COPY

FUNAMIZU et al
Appl. No. 09/485,845
February 12, 2004

COPY

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-3,4-dihydro[1,5]benzothiazepin-5-yl)butyramide;

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-cyano-5-isopropyl-2-exo-2H-cyclohepta-1,6,8-trieno[b]pyrrol-1-yl)propionamide;~~

~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrole[1,2-a][1,1]diazepin-10-yl)propionamide;~~ and

N-[1(R)-[2-Hydroxy-3-(2(R)-hydroxypropylamino)propylcarbamoyl]-2-naphthalen-2-yl-ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide.

68. (Previously Presented) A composition which comprises an inert carrier and a compound according to claim 85.

69. (Currently Amended) A composition which comprises an inert carrier, a compound according to claim 85 and at least one of the following components:
a growth hormone secretagogues selected from KP-102(GHRP-2),GHRP-6, Hexarelin, and GHRP-1,
a growth hormone releasing factor (GRF) selected from IGF-1, IGF-2 and B-HT920, and a growth hormone.

70. (Previously Presented) A method for increasing levels of endogenous growth hormones in a human or an animal which comprises administering to such human or animal an effective amount of a compound according to claim 85.

FUNAMIZU et al
Appl. No. 09/485,845
February 12, 2004

COPY

71. (Previously Presented) A method for treating diseases or conditions which may be treated by growth hormone which comprises administering to a human or an animal of such treatment an amount of a compound according to claim 85 which is effective in promoting release of said growth hormone.

72. (Previously Presented) A method of claim 71 wherein the disease or condition is selected from the group consisting of osteoporosis; catabolic illness; immune deficiency, hip fracture; musculoskeletal impairment in the elderly; growth hormone deficiency in adults or in children; obesity; cachexia and protein loss due to chronic illness and treatment of patients recovering from major surgery, wounds and burns.

73. (Previously Presented) A method for increasing the level of growth hormone in a human or an animal which comprises administering to a human or animal a compound according to claim 85 in combination with any one of the following components:

an additional growth hormone secretagogue selected from KP-102(GHRP-2), GHRP-6, Hexarelin and GHRP-1, a growth hormone releasing factor(GRF) selected from IGF-1, IGF-2 and B-HT920, and a growth hormone.

74. (Previously Presented) A method for the treatment of osteoporosis which comprises administering to a patient with osteoporosis a combination of a bisphosphonate compound and a compound according to claim 85.

75. (Previously Presented)) A method for the treatment of bone fractures, wounds or burns which comprises administering to a patient with bone fractures, wounds or

BEST AVAILABLE COPY

FUNAMIZU et al
Appl. No. 09/485,845
February 12, 2004


COPY

burns a combination of fibroblast growth factor (FGF) or platelet-derived growth factor (PDGF) and a compound of claim 85.

76. (Previously Presented) A method to increase the rate and extent of growth of animals, to increase the milk or wool production of animals the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 85.

77-84. Canceled

85. (Previously Presented) A compound having the following formula:






wherein

A₁ is


REST AVAILABLE COPY

FUNAMIZU et al
Appl. No. 09/485,845
February 12, 2004

COPY




M is



or

B is



or






, and

DEST AVAILABLE COPY

FUNAMIZU et al
Appl. No. 09/485,845
February 12, 2004

COPY

D is



BEST AVAILABLE COPY